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Abstract
The relationship of gut microbiota and calcium oxalate stone has been limited investi-
gated, especially with no study of gut microbiota and short chain fatty acids (SCFAs) 
in nephrolithiasis. We provided Sprague Dawley rats of renal calcium oxalate stones 
with antibiotics and examined the renal crystals deposition. We also performed a 
case-control study by analyzing 16S rRNA microbial profiling, shotgun metagenom-
ics and SCFAs in 153 fecal samples from non-kidney stone (NS) controls, patients 
with occasional renal calcium oxalate stones (OS) and patients with recurrent stones 
(RS). Antibiotics reduced bacterial load in feces and could promote the formation of 
renal calcium crystals in model rats. In addition, both OS and RS patients exhibited 
higher fecal microbial diversity than NS controls. Several SCFAs-producing gut bac-
teria, as well as metabolic pathways associated with SCFAs production, were consid-
erably lower in the gut microbiota among the kidney stone patients compared with 
the NS controls. Representation of genes involved in oxalate degradation showed no 
significance difference among groups. However, fecal acetic acid concentration was 
the highest in RS patients with high level of urinary oxalate, which was positively 
correlated with genes involvement in oxalate synthesis. Administration of SCFAs 
reduced renal crystals. These results shed new light on bacteria and SCFAs, which 
may promote the development of treatment strategy in nephrolithiasis.
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1 |  INTRODUCTION
Nephrolithiasis, with a worldwide prevalence rate of 5%-
10%, is one of the most common urologic diseases.1,2 Kidney 
stone (KS) returns frequently with a recurrence rate of 6%-
17% within one year, 21%-53% within three to five years, 
and a lifetime recurrence rate of 60%-80%.2 Nephrolithiasis 
has increasingly strained the health care system with high 
prevalence, severe pain to patients, and burdensome med-
ical costs.
Calcium oxalate stone is the most common type of KS, 
accounting for 60%-90% of the cases.2 Limited knowledge 
of the mechanisms underlying stone formation has been 
available. For example, it is known that KS formation may 
result from poor fluid intake, high temperature, or excessive 
consumption of high oxalate foods, which could increase 
urinary excretion of oxalate.2 The oxalate in the body was 
directly absorbed from diet, and produced by the liver as 
the final metabolite product of many metabolites, such as 
glyoxalate, glycine, hydroxyproline, and ascorbic acid.3 
Recently, Tasian et al reported that antibiotic exposure 
was associated with an increasing nephrolithiasis preva-
lence, which indicated that the intestinal microbiota may 
affected the formation of renal calcium oxalate stone.4 In 
addition, some studies have found that intestinal microbiota 
was related to calcium oxalate stone with the discovery of 
Oxalobacter formigenes, which could degrade oxalate.5-7 
Thus, the underlying mechanisms of the formation of renal 
calcium oxalate stones remain obscure, and need more in-
depth exploration.
Short chain fatty acids (SCFAs), as a major product from 
the microbial fermentative activity in the gut, have been in-
volved in energy metabolism, hormone secretion, immune 
inflammation, and cancer.8,9 While growing evidence has 
suggested that SCFAs play an important role in kidney dis-
ease through the gut-kidney axis by regulating inflammation, 
oxidative stress, and fibrosis,10,11 SCFAs in nephrolithiasis 
are rarely explored.
Recently, the emerging techniques in 16S rRNA amplicon 
sequencing and shotgun metagenomics have enabled us to 
better understand the roles of gut microbiota in the formation 
of renal calcium oxalate stones. This study, to our knowledge, 
registers the first attempt to disclose the relationship between 
gut microbiota and short chain fatty acids in renal calcium 
oxalate stones and non-kidney stones.
2 |  MATERIALS AND METHODS
2.1 | Renal calcium oxalate stone models 
and treatment regimes
We purchased Sprague Dawley rats (6-week-old, male) 
(Dossy Experimental Animals Co., Ltd, Chengdu, Sichuan, 
China). The animal experiment was performed in accord-
ance with the policies of the West China Hospital of Sichuan 
University Medical Research Ethics Committee (2017063A). 
Twenty rats were randomly divided into four groups. Rats 
were first acclimatized for 1 week before experiment in the 
specific pathogen free animal facility with free access to 
standard food and water at Animal Experiment Center of 
West China Hospital, Sichuan University. Rats in control 
group had free access to drinking water. Antibiotics group 
rats received an extra cocktail of antibiotics resolved into 
drinking water, including 0.5 mg/mL of ampicillin, 0.5 mg/
mL of metronidazole, 0.5 mg/mL of neomycin, and 0.25 mg/
mL of vancomycin. Ethylene glycol (EG) group rats received 
drinking water containing 1% (v/v) EG. EG  +  antibiotics 
group rats had 1% (v/v) EG and antibiotics at the same time. 
Another 25 rats were also randomly divided into five groups, 
including control, EG, EG  +  Acetate, EG  +  Propionate, 
and EG + Butyrate groups. The last three groups received 
drinking water with EG plus sodium acetate, sodium pro-
pionate, and sodium butyrate, respectively. The amount of 
drinking water was recorded every three days, and the body 
weight of rats was recorded every week. After 4 weeks, we 
injected chloral hydrate (4% (w/v), 0.8  ml/100g) (JUHUI 
CHEMICAL, Chengdu, Sichuan, China) intraperitoneally 
to euthanize rats and collected kidneys and feces in colon. 
Kidneys were stored in 10% of formaldehyde and fixed in 
paraffin. Feces were stored at −80°C.
We extracted microbial DNA from fecal samples using 
Qiamp Fast DNA Stool extraction kit (Qiagen, Hilden, 
Nordrhein-Westfalen, Germany) according to manufac-
turer's protocols. Then, we amplified DNA with primers 
27F (5′-AGAGTTTGATCMTGGCTCAG-3′) and 1492R 
(5′-CGGTTACCTTGTTACGACTT-3′).
Kidneys were stained with Hematoxylin & Eosin (HE) 
and Von Kossa (VK) using HE staining kit (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) and VK staining 
kit (Solarbio, Beijing, China) according to the manufactur-
er's protocols. HE staining scoring system reported by Xiang 
K E Y W O R D S
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et al was used to examine the formation of crystals.12 The 
level of calcium oxalate crystals in VK staining was evalu-
ated by image pro plus6 software.
2.2 | Human study designs, 
subjects, and sampling
A case-control study was performed at the West China Hospital 
in China from June 2018 to August 2019. Patients were diag-
nosed as renal stone by using the X-ray of kidney-ureter-blad-
der, ultrasound of the urinary system, or abdominal computed 
tomography. All patients received percutaneous nephroli-
thotomy or flexible ureteroscopy. Patients with at least two 
episodes of renal stones and those who had renal stones within 
one year after surgery by follow-up were regarded as recurrent 
stones (RS) patients. All the other KS patients were considered 
as occasional stones (OS) patients. To eliminate the bias caused 
by age, we mainly recruited non-kidney stone (NS) controls 
without renal stones between 40 and 60. They were confirmed 
by the absence of the history of renal colic and of renal stones 
using abdominal ultrasonic examination in Health Promotion 
Center of West China hospital. This study was approved by the 
West China Hospital of Sichuan University Medical Research 
Ethics Committee (2018182), and informed consents were ob-
tained from each participant.
The following types of KS patients were excluded: non-cal-
cium oxalate stones, infectious stones, abnormality of the uri-
nary system, hyperthyroidism, hyperparathyroidism, long-term 
use of drugs that may cause KS. The component of renal stones 
was confirmed by infrared spectroscopy. Participants were also 
excluded if they used antibiotics or immunosuppressants within 
three months before fecal sampling, had inflammatory bowel 
disease, irritable bowel syndrome, digestive tract infection, tu-
mors of the digestive system, intestinal surgery, or diarrhea or 
constipation within one month before fecal sampling.
A questionnaire was designed to query participants’ de-
mographic information, dietary habits, sitting, and sleeping 
time, history of smoking and alcohol, family history of stone 
and history of metabolic diseases and surgery. Body mass 
index was calculated by dividing weight in kilograms by the 
square of height in meters. Fecal and urinary samples from 
each participant were collected during the visit of the clinic 
of Urology of West China Hospital, prior to any treatment, 
such as antibiotics. Samples were immediately frozen in 
liquid nitrogen, and subsequently stored under −80°C until 
analysis.
2.3 | 16S rRNA microbial profiling analyses
Microbial DNA was extracted from the fecal samples by using 
QIAamp Fast DNA Stool Mini Kit, Cat# 51604 (Qiagen, Germany) 
according to the manufacturer's protocol. The V3-V4 hypervar-
iable regions of the bacteria 16S rRNA gene were amplified 
with primers 338F (5′-ACTCCTACGGGAGGCAGCAG-3′) 
and 806R (5′-GGACTACHVGGGTWTCTAAT-3′) by PCR 
system (GeneAmp 9700, ABI, USA). The resulting PCR 
products were extracted from a 2% of agarose gel and further 
purified by using the AxyPrep DNA Gel Extraction Kit, Cat# 
AP-GX-50 (Axygen Biosciences, USA) and quantified by 
using QuantiFluor-ST (Promega, USA) according to the manu-
facturer's protocol. Then, purified amplicons were pooled in 
equimolar and paired-end sequenced (2 × 300) on an Illumina 
MiSeq platform (Illumma, San Diego, USA) according to the 
standard protocol.
Raw fastq files were quality-filtered by Trimmomatic and 
merged by FLASH. All the sequences were clustered into dif-
ferent operational taxonomic units (OTUs) at 97% similarity 
using UPARSE (version7.1 http://drive5.com/upars e/), and 
chimeric sequences were identified and removed by using 
UCHINIE. The taxonomy of each 16S rRNA amplicon se-
quence was analyzed by the RDP Classifier algorithm (http://
rdp.cme.msu.edu/) against the Silva (SSU132) 16S rRNA da-
tabase with the confidence threshold of 70%. Each sample 
was rarefied to the same amount of sequences (10 000).
We compared alpha diversity indices, such as Chao, ACE, 
Shannon, and Simpson across the OS, RS, and NS groups. 
Coverage index was calculated to determine if the sequencing 
depth covered the whole bacterial diversity. Inter-individual 
variability (beta diversity) among these three groups was 
evaluated by the principal coordinates analysis (PCoA) and 
the Adonis test. Linear discriminant analysis Effect Size 
(LEfSe) analysis was used to identify differentially abundant 
bacteria among the three groups with a cutoff of 2.0. The 
Kyoto Encyclopedia of Genes and Genomes metabolic path-
ways were predicted by the PICRUSt package.
2.4 | Shotgun metagenomics analysis of 
fecal samples
DNAs extracted from 15 fecal samples (five NS controls, five 
OS patients, and five RS patients), representing the average 
composition of controls and KS patients, were used for deep 
shotgun metagenomics sequencing. Bacterial DNAs were 
extracted from stool samples. The metagenome sequencing 
was performed and analyzed using Illumina Hiseq system. 
The raw sequences were decoded, denoised, trimmed, and 
assembled for gene prediction by using MetaGene (http://
metag ene.cb.k.u-tokyo.ac.jp/). The predicted genes were 
clustered (with identity of 95% and coverage of 95%) by CD-
HIT (http://www.bioin forma tics.org/cd-hit/) into a nonre-
dundant gene catalog. KEGG (Kyoto Encyclopedia of Genes 
and Genomes, http://www.genome.jp/kegg/) databases were 
used to predict gene functions.
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2.5 | Fecal short chain fatty acids 
quantification and detection of urinary oxalate
Fecal SCFAs were measured using gas chromatography-mass 
spectrometry. Each SCFA was calculated from a calibration 
curve produced for serially diluted SCFA standards. The 
SCFA calibration curve was linear (R2 ≥ 0.999). Urinary ox-
alate was measured and analyzed by liquid chromatography-
mass spectrometry. The oxalate calibration curve was linear 
(R2  =  0.999). The mean recovery of oxalic acid of known 
concentration added to urine samples was 92.91%-99.25%.
2.6 | Statistical analysis
Continuous variables were summarized with mean and stand-
ard deviation if they were symmetrically distributed. Otherwise, 
they were reported with median and interquartile range (IQR). 
Analysis of variance (ANOVA), Kruskal-Wallis test, and 
Mann-Whitney test were used for testing quantitative variables, 
and Chi-square test was used for categorical variables. All sta-
tistical analyses were performed with R v.3.6.0 (R Project for 
Statistical Computing, www.r-proje ct.org).
3 |  RESULTS
3.1 | Effect of antibiotics on gut microbiota 
and renal calcium oxalate crystals
To verify the role of gut microbiota in renal calcium oxalate 
stone, we directly depleted bacterial load in rat gut with an-
tibiotics. All rats were alive at the end of experiment after 
four weeks. The change of body weight of rats was shown in 
Figure S1A). The amount of drinking water of rats was not 
different between EG and EG  +  Antibiotics groups (Figure 
S1B). Rat fecal bacterial load decreased sharply by 150 times 
after administration of antibiotics, when compared to the con-
trol group (Figure 1A,B). Then, we observed the formation of 
renal crystals in rat kidney with or without administration of 
antibiotics. The result showed that EG successfully induced 
the formation of renal crystals in rat kidney (Figure 1C,D,E). 
Furthermore, VK staining showed that antibiotics significantly 
promoted the formation of renal crystals (Figure 1C,E).
3.2 | General characteristics of non-kidney 
stone controls, occasional, and recurrent 
stone patients
To identify what specific bacteria were associated with renal 
calcium oxalate stone, we recruited 76 renal stone patients. 
Seven of them were excluded because their renal stones were 
infectious stones or not calcium oxalate. Finally, 69 KS patients 
(26 RS patients and 43 OS patients) and 84 NS controls were 
enrolled (Figure S1C). Age (P = .460) and BMI (P = .198) 
were not significantly different among RS, OS, and NS groups. 
However, the distribution of gender was significantly different 
among the RS, OS, and NS groups (76.9% male in RS, 65.1% 
male in OS, and 40.5% male in NS, P = .001). Consumption 
of fat or red meat, intake of milk and fruit, sitting and sleeping 
time, active smoking, family history of KS, hypertension, and 
nonalcoholic fatty liver disease (NAFLD) were significantly 
different among NS, OS, and RS groups (Table 1). The re-
sults of a multiple logistic regression model, after controlling 
for these ten variables, indicated that less fruit intake, sitting 
longer, hypertension, and NAFLD were associated with occur-
rence of renal calcium oxalate stones (Table 2).
3.3 | Richness and diversity of the gut 
microbiota in KS patients and NS controls
The fecal samples from 153 participants were applied to 16S 
rRNA sequence analysis. A total of 8,026,841 high-quality 
sequences were obtained from these 153 samples with an 
average length of 436. All the sequences were clustered into 
1108 OTUs, which belonged to 442 genera and 23 phyla. The 
coverage indices of the NS, OS, and RS groups were 98.34%, 
97.97%, and 97.98%, respectively. In addition, nearly all the 
rarefaction curves reached the saturation plateau (Figure S1D).
The Wilcoxon rank-sum test showed that alpha diver-
sity indices (Ace and Chao), representing the richness of 
gut microbiota, were higher in KS patients than in controls 
(Figure 2A, Table S1). There were no statistically significant 
differences in Shannon and Simpson indices across the NS, 
OS, and RS groups (Figure 2A, Table S1). PCoA at the OTU 
level showed that the overall microbiota composition of the 
NS, OS, and RS groups were different, which was confirmed 
by the Adonis test (R2 = 0.031, P = .002) (Figure 2B).
3.4 | Taxonomic analysis of microbiota 
composition between KS patients and NS controls
Taxonomic assignment of the OTUs revealed the compo-
sition of the bacterial population down to the phylum and 
genus level. At the phylum level, Firmicutes (61.4%) was 
the most common bacteria in gut microbiota, followed by 
Bacteroidetes (18.9%) and Proteobacteria (11.7%). The ratio 
of Firmicutes/Bacteroidetes was higher in KS patients than 
that in NS controls (3.70 vs 2.72). At the genus level, the 
common bacteria of 153 samples were Bacteroides (9.8%), 
Fecalibacterium (9.5%), Blautia (4.5%), Escherichia-
Shigella (4.4%), Megamonas (4.2%), Lactobacillus (4.1%), 
and [Eubacterium]-rectale-group (4.0%) (Figure 2C).
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F I G U R E  1  Effect of antibiotics on gut microbiota and renal calcium oxalate crystals in rats (n = 5/group). Rats received an extra cocktail of 
antibiotics resolved into drinking water, including 0.5 mg/mL of ampicillin, 0.5 mg/mL of metronidazole, 0.5 mg/mL of neomycin, and 0.25 mg/
mL of vancomycin with or without ethylene glycol. Rat microbial DNA from fecal samples were detected before (A) and after (B) antibiotics 
administration. The level of calcium oxalate stones was evaluated by image pro plus6 software using Von Kossa (VK) staining. Three different 
sections of each Von Kossa staining were selected, which resulted in 15 data in Figure 1C (C and E). Kidneys were also stained with Hematoxylin-
Eosin (HE), and HE staining scoring system was used to examine the formation of crystals (D and E)
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To identify the association between calcium oxalate 
stones and gut bacteria, LEfSe analysis was used to compare 
bacteria among NS controls, OS patients, and RS patients. At 
T A B L E  1  Comparison of general characteristics between NS 
controls, OS and RS patients
NS controls OS patients RS patients P value
Age 50.4 (7.0) 50.6 (12.0) 53.0 (11.1) .460a
BMI 24.4 (2.5) 23.6 (2.9) 24.7 (3.5) .198a
Gender
Female 50 (59.5%) 15 (34.9%) 6 (23.1%) .001b




30 (35.7%) 14 (32.6%) 7 (26.9%) .604b
1000-2000 
(mL/day)
31 (36.9%) 14 (32.6%) 13 (50.0%)
>2000 (mL/
day)
23 (27.4%) 15 (34.9%) 6 (23.1%)
Salt
Less-salt 27 (32.1%) 11 (25.6%) 3 (11.5%) .345b
Medium-salt 43 (51.2%) 23 (53.5%) 17 (65.4%)
More-salt 14 (16.7%) 9 (20.9%) 6 (23.1%)
Fat
Less-fat 31 (36.9%) 3 (7.0%) 2 (7.7%) .001b
Medium-fat 35 (41.7%) 25 (58.1%) 17 (65.4%)
More-fat 18 (21.4%) 15 (34.9%) 7 (26.9%)
Spicy
Non-spicy 11 (13.1%) 11 (25.6%) 7 (26.9%) .094b
Medium-spicy 53 (63.1%) 17 (39.5%) 12 (46.2%)





58 (69.0%) 30 (69.8%) 19 (73.1%) .420b
10-20 (times/
month)
14 (16.7%) 3 (7.0%) 4 (15.4%)
>20 (times/
month)




67 (79.8%) 27 (62.8%) 15 (60.0%) .172b
10-20 (times/
month)
2 (2.4%) 1 (2.3%) 1 (4.0%)
>20 (times/
month)
15 (17.9%) 15 (34.9%) 9 (36.0%)
Red meat
<100 (g/day) 67 (79.8%) 28 (65.1%) 18 (69.2%) .004b
100-200 (g/day) 15 (17.9%) 6 (14.0%) 7 (26.9%)
>200 (g/day) 2 (2.4%) 9 (20.9%) 1 (3.8%)
Milk
<250 (mL/day) 54 (64.3%) 37 (86.0%) 22 (84.6%) .012b
>250 (mL/day) 30 (35.7%) 6 (14.0%) 4 (15.4%)
(Continues)
NS controls OS patients RS patients P value
Fruit
<200 (g/day) 42 (50.0%) 31 (72.1%) 20 (76.9%) .010b
>200 (g/day) 42 (50.0%) 12 (27.9%) 6 (23.1%)
Sitting time
<4 (h/day) 67 (79.8%) 12 (27.9%) 6 (23.1%) <.001b
4-7 (h/day) 17 (20.2%) 19 (44.2%) 9 (34.6%)
>7 (h/day) 0 (0.00%) 12 (27.9%) 11 (42.3%)
Sleeping time
<6 (h/day) 5 (6.0%) 10 (23.3%) 7 (26.9%) .022b
6-9 (h/day) 77 (91.7%) 32 (74.4%) 19 (73.1%)
>9 (h/day) 2 (2.4%) 1 (2.3%) 0 (0.00%)
Smoking
No 67 (79.8%) 22 (51.2%) 20 (76.9%) .003b
Yes 17 (20.2%) 21 (48.8%) 6 (23.1%)
Alcohol
No 60 (71.4%) 28 (65.1%) 20 (76.9%) .562b
Yes 24 (28.6%) 15 (34.9%) 6 (23.1%)
Family history of 
stone
No 73 (86.9%) 26 (60.5%) 15 (57.7%) <.001b
Yes 11 (13.1%) 17 (39.5%) 11 (42.3%)
Diabetes mellitus
No 80 (95.2%) 39 (90.7%) 21 (80.8%) .067b
Yes 4 (4.8%) 4 (9.3%) 5 (19.2%)
Hypertension
No 80 (95.2%) 30 (69.8%) 15 (57.7%) <.001b
Yes 4 (4.8%) 13 (30.2%) 11 (42.3%)
NAFLD
No 80 (95.2%) 36 (83.7%) 19 (73.1%) .005b




No 80 (95.2%) 37 (86.0%) 21 (80.8%) .053b
Yes 4 (4.8%) 6 (14.0%) 5 (19.2%)
Gastritis or 
enteritis
No 74 (88.1%) 37 (86.0%) 19 (73.1%) .169b
Yes 10 (11.9%) 6 (14.0%) 7 (26.9%)
Note: aAnalysis of variance (ANOVA). bChi-square test. NS, non-kidney stone. 
OS, occasional stones. RS, recurrent stones. BMI, body mass index. NAFLD, 
nonalcoholic fatty liver disease.
T A B L E  1  (Continued)
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the genus level, 10, 17, and 21 significantly different bacteria 
exhibited in NS controls, OS and RS patients, respectively 
(P < .05) (Table S2).
In addition, when comparing NS controls vs KS patients, 
15 and 40 significantly different bacteria genera were abun-
dant in the gut microbiota of NS and KS patients (P < .05) 
(Table  S3). When comparing the gut microbiota between 
OS and RS patients, only three (Eubacterium, Lautropia, 
and Ruminococcaceae_UCG_005) and four bacteria 
(Blautia, Eubacterium_hallii_group, Fusicatenibacter, and 
Lachnospiraceae_ND3007_group) were higher in OS and 
RS patients, respectively (P < .05).
3.5 | Metabolic function of gut microbiota
Based on the classification of bacteria by using 16S data, dif-
ferentially abundant metabolic pathways were detected among 
OS, RS patients and NS controls. LEfSe analysis revealed 
that the abundance of porphyrin and chlorophyll metabolism 
(ko00860) was higher in NS controls, and that of citrate cycle 
(ko00020) was higher in KS patients (Figure  2D). When 
comparing between NS controls and KS patients (OS/RS), 
more abundant metabolic pathways related to inflammation 
and oxidative stress, such as lipopolysaccharide (LPS) bio-
synthesis (ko00540), were identified among KS patients. On 
the contrary, the abundance of pathways in methane metabo-
lism (ko00680), arginine and proline metabolism (ko00330) 
were higher in NS Controls (P < .05) (Figure 2D).
3.6 | Taxonomic analysis of gut microbiota 
between NS controls and KS patients selected 
by propensity score match (PSM)
To eliminate the possible confounding effects of the above-
mentioned factors (such as gender, hypertension, and 
NAFLD), we selected 24 NS controls and 24 KS patients by 
using PSM, which was a statistical tool to balance the possi-
ble confounders across comparison groups tool.13 These fac-
tors were not statistically different between these two groups 
after this operation (P >  .05) (Table S4). Using LEfSe, we 
found 12 and 27 significantly different bacteria genera in the 
gut microbiota of NS and KS patients (Table S5) (P < .05). 
The results were similar before and after PSM.
3.7 | Functional analysis of fecal microbiota 
by metagenomics
To investigate the functional profile of the gut microbiome in 
KS patients, we also performed metagenomics analysis of the 
microbial DNA extracted from fecal samples of OS, RS pa-
tients and NS controls. A total of 678,658,648 filtered reads 
and 4,037,497 ORFs were used for functional annotation in 
the KEGG databases.
LEfSe analysis of metagenomics data was used to compare 
bacteria among NS controls, OS and RS patients at the spe-
cies level, and detected nine significantly different bacteria 
exhibited between NS controls and KS patients (Figure 3A). 
When comparing between OS and RS patients, only three 
significantly different bacteria (Thermorudis_peleae, 
T A B L E  2  Multivariate logistic regression analysis for risk and 
protective factors of kidney stone patients







Less-fat 0.018 −1.569 −2.866 −0.272
Medium-fat 0.267 −0.529 −1.463 0.405
More-fat 0
Red meat
<100 (g/day) 0.743 0.245 −1.220 1.710
100-200 (g/day) 0.771 −0.243 −1.879 1.394
>200 (g/day) 0
Milk
<250 (ml/day) 0.473 0.364 −0.631 1.360
>250 (ml/day) 0
Fruit
<200 (g/day) 0.003 1.335 0.455 2.215
>200 (g/day) 0
Sitting time
<4 (h/day) <0.001 −3.326 −4.629 −2.024
4-7 (h/day) <0.001 −2.402 −3.631 −1.173
>7 (h/day) 0
Sleeping time
<6 (h/day) 0.677 0.626 −2.318 3.570
6-9 (h/day) 0.428 −1.145 −3.974 1.684
>9 (h/day) 0
Smoking
No 0.744 0.142 −0.710 0.995
Yes 0
Family history of stone
No 0.132 −0.687 −1.581 0.207
Yes 0
Hypertension
No 0.003 −1.485 −2.478 −0.492
Yes 0
NAFLD
No 0.043 −1.244 −2.447 −0.040
Yes 0
Abbreviations: CIs, confidence intervals; NAFLD, nonalcoholic fatty liver 
disease.
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Salsuginibacillus_kocurii, and Sebaldella_termitidis) were 
found at the species level (Figure 3B).
We further determined changes in functional composition 
by using the KEGG pathway database (P  <  .05). Pearson 
correlations between different gut microbiota and different 
KEGG Orthology (KO) or gene pathways among NS controls, 
OS patients and RS patients were shown in Figures 4 and 5. 
Predominant Lactobacillus_diolivorans in OS patients was 
positively correlated with biofilm formation. Predominant 
Fictibacillus_phosphorivorans in OS patients were positively 
correlated with benzoate degradation, phenylalanine metabo-
lism, biofilm formation, beta-Alanine metabolism and capro-
lactam degradation.
Moreover, predominant Enterococcus_faecium in OS 
patients were positive correlated with isoquinoline alkaloid 
biosynthesis, limonene and pinene degradation, benzoate 
degradation, phenylalanine metabolism, biofilm formation, 
propanoate metabolism, tropane, piperidine and pyridine al-
kaloid biosynthesis, beta-Alanine metabolism, butanoate me-
tabolism, and caprolactam degradation.
However, predominant Xanthobacter_sp__126 in RS pa-
tients was positive correlated with carotenoid biosynthesis. 
Predominant Lentisphaera_araneosa, Arenitalea_lutea, and 
Akkermansia_sp__KLE1605 in RS patients were all positive 
correlated with sesquiterpenoid and triterpenoid biosynthesis 
and carotenoid biosynthesis (Figure 5).
3.8 | Oxalate degradation genes in gut 
microbiota and oxalate levels in urine
RS patients presented a higher median urinary oxalate 
(18.10 μg/mL) than OS patients (8.53 μg/mL) and NS con-
trols (4.60 μg/mL). The Kruskal-Wallis test showed that the 
F I G U R E  2  Analysis of fecal microbiota among non-kidney stone (NS) controls (n = 84), occasional stone (OS) patients (n = 43) and 
recurrent stone (RS) patients (n = 26) by using 16s rRNA. A, Comparison of alpha diversity of gut microbiota between NS controls, OS and RS 
patients. Ace, Chao, Shannon, and Simpson indices at operational taxonomic units (OTUs) level were compared between NS controls (green), OS 
(blue), and RS patients (red) by the Wilcoxon rank-sum test (**P < .01). B, Comparison of beta diversity of gut microbiota between NS controls, 
OS and RS patients. PCoA score plot based on binary pearson distance at OTUs level revealed classification of NS controls, OS and RS patients. 
Green diamond represented NS controls. Blue triangle represented OS patients. Red points represented RS patients. C, The composition of gut 
microbiota in NS controls, OS and RS patients at phylum or genus level. D, The associations of differential bacteria with differential metabolic 
pathways in the NS controls and kidney stone (KS) patients (OS + RS)
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F I G U R E  3  Analysis of fecal microbiota among non-kidney stone (NS) controls (n = 5), occasional stone (OS) patients (n = 5) and recurrent 
stone (RS) patients (n = 5) by using 16s rRNA at species level using metagenomics. A, The different bacteria between NS controls and kidney 
stone (KS) patients (OS + RS) (P < .05). B, The different bacteria between OS patients and RS patients (P < .05). (* P < .01)
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median urinary oxalate was significantly different across 
the groups (P =  .004). However, based on metagenomics 
analysis, the fecal microbiota of metagenomics data pre-
sented no significant differences in the abundance of O for-
migenes (P = .744), genes involved in oxalate degradation 
(formyl-CoA transferase (P = .254) and oxalyl-CoA decar-
boxylase (P = .216)) between KS patients and NS controls 
(Figure S1E-G).
3.9 | Fecal SCFAs concentrations 
correlate with abundance of distinct bacterial 
taxonomic groups
Pearson correlation was used to quantify the associations of 
different bacteria and the abundance of metabolic pathways 
in NS patients and KS patients, separately. Interestingly, 
using the 16S data, the abundance of pathways involved in 
F I G U R E  4  Heatmap showing pearson correlation between different KEGG Orthology (KO) and different microbial taxa identified by 
metagenome sequence-based analysis in non-kidney stone (NS) controls (n = 5), occasional stone (OS) patients (n = 5) and recurrent stone (RS) 
patients (n = 5)
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SCFAs production was positively correlated with the level of 
bacteria higher in the gut microbiota of NS controls, but was 
negatively correlated with that of KS patients (Figure 6A), 
which indicated that the gut microbiota of NS controls may 
tend to produce more SCFAs than KS patients.
To validate the role of SCFAs in renal calcium oxa-
late stones, we evaluated the fecal SCFAs concentration 
in NS controls, OS and RS patients. The concentration 
of acetic acid in the feces was higher in RS patients (me-
dian  =  53.20  μg/mg, IQR  =  28.17  μg/mg) than that in 
OS patients (45.63  μg/mg, IQR  =  37.41  μg/mg) and NS 
controls (median  =  21.44  μg/mg, IQR  =  10.22  μg/mg) 
(P < .001) (Figure 6B, Table S6).
We explored the relationship between the fecal SCFAs 
concentrations and the abundance of bacterial taxonomic 
groups. Using 16S data, we found that butanoic acid-3-
methyl, pentanoic acid, and hexanoic acid were highly cor-
related with taxa belonging to Ruminococcaceae_UCG_005 
in NS controls (Figure 6C). To investigate the relationship be-
tween the fecal SCFAs and function of gut microbiota among 
groups, metagenomics data was analyzed by Pearson cor-
relation analysis. Propionic acid was highly correlated with 
genes for araE (K02100) and lysE (K06895) in OS patients 
(Figure 6D). In RS patients, acetic acid was positively cor-
related with genes for licA (K16119), shc (K06045), PCCB 
(K01966), pckA (K01596), treS (K17311), treU (K17313), 
hisI (K01496), pdxH (K00275), IMPDH (K00088), mexY 
(K18095), and secG (K03075), which were involved in the 
pathways of metabolism of terpenoids and polyketides, car-
bohydrate metabolism, membrane transport, amino acid 
metabolism, metabolism of cofactors and vitamins, nucleo-
tide metabolism, signal transduction, and genetic information 
processing, respectively (Figure 6D).
We found high fecal concentration of acetic acid was highly 
positively correlated with glyoxylate and dicarboxylate metabo-
lism (PCCB, K01966) in RS patients with high level of urinary 
oxalate. We further investigated the bacterial taxonomic groups 
related to glyoxylate and dicarboxylate metabolism (PCCB, 
K01966) among NS controls, OS and RS patients. The results 
showed that the abundance of s__Ruminococcaceae_bacte-
rium_AE2021 association with PCCB was significant higher in 
KS patients than that in NS controls (P < .05) (Figure 6E).
3.10 | Effect of SCFAs on renal calcium 
oxalate crystals
To verify the effect of SCFAs on the formation of renal cal-
cium oxalate crystals, we gave different SCFAs to renal cal-
cium oxalate stone model rats. HE and VK staining showed 
that renal crystals reduced after four weeks’ administration of 
acetate, propionate, or butyrate (Figure 7). The results dem-
onstrated that SCFAs could effectively prevent the formation 
of renal calcium oxalate crystals.
4 |  DISCUSSION
Our study found that depletion of gut microbiota with anti-
biotics could promote the formation of renal crystals in rats, 
F I G U R E  5  Heatmap showing pearson correlation between different KEGG pathways and different microbial taxa identified by metagenome 
sequence-based analysis in non-kidney stone (NS) controls (n = 5), occasional stone (OS) patients (n = 5), and recurrent stone (RS) patients (n = 5)
   | 11211LIU et aL.
F I G U R E  6  Analysis of fecal short chain fatty acids (SCFAs) and gut microbiota among non-kidney stone (NS) controls (n = 84), occasional 
stone (OS) patients (n = 43) and recurrent stone (RS) patients (n = 26). A, The associations of differential bacteria in NS controls and KS patients 
with pathways involved in SCFAs production. B, The levels of acetate, propionate, and butyrate among NS controls, OS and RS patients. The 
levels of acetic acid, propionic acid, and butyric acid among NS controls, OS and RS patients by Mann-Whitney test (*P < .05, ***P < .001). C, 
The correlation between SCFAs and gut microbiota. D, The correlation between SCFAs and function of gut microbiota by Pearson correlation 
analysis. E, The abundance of s__Ruminococcaceae_bacterium_AE2021 association with PCCB between healthy controls and patients with kidney 
stone
F I G U R E  7  Effect of SCFAs on renal calcium oxalate crystals (n = 5/group). Rats received drinking water with EG plus sodium acetate, 
sodium propionate, and sodium butyrate, respectively, for 4 weeks. Hematoxylin-Eosin (HE) and Von Kossa (VK) staining showed that three kind 
of SCFAs all could reduce renal calcium oxalate crystals
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and then, we investigated gut microbiota profiles and fecal 
SCFAs in relation to patients with occasional and recurrent 
renal calcium oxalate stones.
We found that several bacteria were higher in NS controls’ 
gut microbiota compared with those in the KS patients. They 
were Blautia, Anaerostipes, Coprococcus, Fusobacterium, 
Ruminococcus, and Lachnospiraceae, of which the com-
mon abundant metabolic products were SCFAs.14,15 SCFAs 
were known to be the energy sources for enterocytes, which 
can maintain gut barrier function and in turn decrease per-
meability of gut, circulating LPS, and systemic inflamma-
tion.16-18 SCFAs can also enter the circulation of the host 
and reach kidneys to ameliorate inflammatory responses and 
fibrotic progress in chronic kidney disease.9,19 Our in vivo 
study also demonstrated that SCFAs like acetate, propionate, 
and butyrate could reduce renal calcium oxalate stones in 
model rats.
This study identified s_Anaerobiospirillum succinic-
iproducens, s_Veillonella atypica, and s_Conexibacter 
woesei associated with SCFAs, exhibited significantly 
higher abundance in NS controls than those in KS patients. 
Anaerobiospirillum succiniciproducens was reported to pro-
duce succinic acid,20 through which propionate can be formed 
by lactate.21 Veillonella atypica was found to utilize lactate 
as their sole carbon source into propionate.22 Hugenholtz 
et al found C woesei preferred acetic acid and propionic acid 
for utilization.23 However, in this study fecal acetic acid was 
higher in KS patients than in NS controls, suggesting that 
less acetic acid was absorbed and utilized by gut, bacteria, or 
other organs (kidney) in renal stone patients.
Pseudomonas, Staphylococcus, Megamonas, 
Synechococcus, Acinetobacter, Cetobacterium, and 
Prevotellaceae_UCG_001 were found in KS patients, which 
were associated with inflammatory diseases,24 indicating 
that inflammation may be involved in formation of renal 
stones. In addition, we found that the abundance of meta-
bolic pathways associated with LPS biosynthesis was higher 
in KS patients. Excessive LPS may aggravate systematic in-
flammation and contribute to the injury of vascular endothe-
lial cell or even renal tubular epithelial cell.25 Halomonas, 
abundant in the gut microbiota of the RS patients tend to 
consume more red meat, was found to be more abundant in 
omnivores than strict vegetarians, and was associated with 
higher interleukin-1.26,27
Previous studies on gut-kidney axis in nephrolithia-
sis were often based on the analysis of O formigenes and 
genes involved in oxalate degradation.28-30 Oxalobacter 
formigenes may degrade oxalate to reduce urinary oxalate 
excretion, and the bacteria enriched in healthy individuals 
tended to have more abundance of O formigenes.29 The re-
sults showed that the abundance of O formigenes and oxa-
late-degrading genes were not different in NS controls and 
KS patients, which suggested that O formigenes may not 
play an important role in renal stone formation with our 
study. Based on 16S data, previous studies demonstrated 
different results that KS patients had higher, lower, or sim-
ilar level of formyl-CoA transferase and oxalyl-CoA decar-
boxylase in the gut microbiota.30-33 A recent randomized 
clinical study reported that there was no difference in blood 
oxalate concentration and stone events between primary hy-
peroxaluria patients with or without probiotics containing 
O formigenes.7 The discrepancy between the studies may 
be attributed to several reasons. First, the included popula-
tion of these studies had different lifestyle, dietary habits, 
living environment, ethnic backgrounds, and disease states, 
all of which would affect the gut microbiota. Second, the 
relative abundance of O formigenes was relatively low in 
the gut microbiota.
Our study showed that shotgun metagenomics sequenc-
ing may identify bacterial species with previously unknown 
oxalate synthesis properties, such as high SCFAs excretion. 
We found a highly expressed bacterial gene that was involved 
in the metabolism of glyoxylate and dicarboxylate (PCCB, 
K01966) among RS patients, and was associated with high 
levels of urinary oxalate and acetic acid excretion. The re-
sults revealed that gut-kidney axis in nephrolithiasis may be 
related to O formigenes and the genes involved in oxalate 
degradation, as well as other bacteria and genes involved in 
oxalate synthesis.
The present study was performed on a limited number of 
people residing in West China, who may not be representa-
tive of the general population. However, our study has several 
strengths as well. First, to our knowledge, this study, which 
focused on the associations between gut microbiota and renal 
calcium oxalate stones, has recruited the largest number of 
Chinese participants among the similar studies. Second, as 
opposed to the studies that did not distinguish occasional and 
recurrent episodes, our study further grouped the KS patients 
into the OS and RS patients. Our refined analyses have shed 
more light on the biological mechanisms underlying the de-
velopment of KS. Finally, we have found, perhaps for the first 
time, that reducing SCFAs absorption and utilization may 
prevent the formation of nephrolithiasis.
In conclusion, the study showed that the depletion of gut 
microbiota promoted the formation of renal crystals. Fecal 
SCFAs dominant patients, with altered gut microbiota com-
position and the functional metagenome, were associated 
with oxalate synthesis. These results shed new light on bac-
teria and genes involved in oxalate synthesis, which may 
help the development of treatment strategy by regulating gut 
microbiota.
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